Mar 31, 2022
MediSieve Presenting at Leading Investor Events
MediSieve has been busy presenting and demonstrating its technology to some of the world's leading investors throughout March.
MediSieve was a presenting company at the virtual 15th Annual European Life Sciences CEO Forum (ELSF) that took place on the 1st-2nd of March. The ELSF is part of Sachs Spring Life Sciences Week which also incorporates the 3rd Annual European HealthTech CEO Forum. This global bio-pharma industry event addressed the main challenges for 2022, including investment, partnering and alliance management. The speakers contributed their insights in panels which covered the macro picture as well as innovation in different therapeutic sectors. The first day focused on Bio Capital & Investment, whilst the second looked at Bio-Pharma Partnering & Therapeutics. Apart from presenting MediSieve's technology, its Founder and CEO, Dr George Frodsham, sat at the Platform Technologies & Novel Therapeutics expert panel and has said that
"It was a real honour to be alongside such esteemed speakers on the panel. The discussion was very interesting and I learnt a lot from the insights of the other panelists. I hope that the discussion was useful for those who watched it, and am looking forward to doing more!"
MediSieve also participated in the MedCity's Pitching Days, which included an online pitching day in February and was followed up by an in-person investor networking event on the 9th of March. The Medcity's Investment Hub featured carefully selected start-ups and university spinouts from across the life sciences industry. MediSieve presented its business and products in person to a select group of Investors alongside other 4 early-stage companies, that have a direct or indirect impact on patients. The event has allowed the company to network and connect with similar business as well as investors. MediSieve is grateful to be part of such a resourceful community.
The company finished off the month by presenting at the MedInvest Pharmaceutical and Biotechnology Investor Conference on the 30-31st of March. MedInvest Conferences are a leading conference series in Healthcare and Life Sciences. The conferences are conducted four times a year, typically focusing on specific indications: oncology, cardiology, neurology, etc. The latest conference focused on drug development and delivery as well as biotech tools and therapies across multiple indications. Dr George Frodsham discussed the latest trends in drug discovery, clinical trials, and market opportunity, exploring new frontiers for business and for healthcare in pharma and biotech alongside other Global Leaders in the Industry. The events featured two days of livestreams with company presentations, keynote talks, and panel discussions as well as four days of one-on-one meetings. The conference hosted companies specializing in drug development and delivery as well as biotech and therapeutics across many indications: oncology, immunology, neurology, cardiology, diabetes, infectious diseases, pulmonary diseases, autoimmune diseases, dermatology, and many others. George has commented that
"It was great to be part of the conference. I enjoyed pitching MediSieve and hopefully it helped our message get out to more people. We were pleased to connect with a number of investors and look forward to continuing those conversations."
MediSieve is delighted to be recognised and invited to such events and panels and hopes to get even more opportunities to talk about its technology as well as network with fellow startups and investors!
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: